Supernus Pharmaceuticals (SUPN) Net Cash Flow Growth (3y) (2014 - 2026)
Supernus Pharmaceuticals (SUPN) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.62 Bn | 23.56 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn | -62.71% |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.36 Bn | - | -46.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.53% |
| Dec 31, 2025 | -7.66% |
| Sep 30, 2025 | 28.68% |
| Jun 30, 2025 | -20.62% |
| Mar 31, 2025 | 36.27% |
| Dec 31, 2024 | 73.01% |
| Sep 30, 2024 | -33.97% |
| Jun 30, 2024 | 29.20% |
| Mar 31, 2024 | 29.32% |
| Dec 31, 2023 | -30.77% |
| Sep 30, 2023 | 132.19% |
| Mar 31, 2023 | 102.59% |
| Dec 31, 2022 | -31.71% |
| Sep 30, 2022 | -60.00% |
| Jun 30, 2022 | 53.67% |
| Mar 31, 2022 | -8.09% |
| Dec 31, 2021 | -29.53% |
| Sep 30, 2021 | -27.97% |
| Jun 30, 2021 | 57.28% |
| Mar 31, 2021 | -27.98% |